MIR196A1

Summary

MIR196A1 (microRNA 196a-1, HGNC:31567) is a microRNA gene on chromosome 17q21.32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406972 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31567
Approved symbol	MIR196A1
Name	microRNA 196a-1
Location	17q21.32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-196-1, hsa-mir-196a-1
Ensembl gene	ENSG00000210741
Ensembl biotype	miRNA
OMIM	608632
Entrez	406972
RNAcentral	URS000014C145 — ncRNA, 70 nt, 15 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000388006

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000388006 — 1 exons

Exon	Start	End
ENSE00001503012	48632490	48632559

Expression profiles

Bgee: expression breadth broad, 46 present calls, max score 96.84.

Top tissues by expression

46 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	96.84	gold quality
heart	UBERON:0000948	96.71	gold quality
mucosa of transverse colon	UBERON:0004991	92.62	gold quality
transverse colon	UBERON:0001157	90.57	gold quality
colon	UBERON:0001155	88.73	gold quality
vermiform appendix	UBERON:0001154	88.12	gold quality
intestine	UBERON:0000160	86.84	gold quality
smooth muscle tissue	UBERON:0001135	83.76	gold quality
small intestine	UBERON:0002108	82.62	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.16	gold quality
lymph node	UBERON:0000029	80.83	gold quality
muscle layer of sigmoid colon	UBERON:0035805	80.52	gold quality
monocyte	CL:0000576	76.71	gold quality
blood	UBERON:0000178	74.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	73.90	gold quality
urinary bladder	UBERON:0001255	73.84	gold quality
kidney	UBERON:0002113	73.71	gold quality
gastrocnemius	UBERON:0001388	73.40	gold quality
stomach	UBERON:0000945	72.23	gold quality
right lobe of liver	UBERON:0001114	70.50	gold quality
tibial artery	UBERON:0007610	70.13	gold quality
adult mammalian kidney	UBERON:0000082	69.32	gold quality
body of uterus	UBERON:0009853	69.06	gold quality
left adrenal gland	UBERON:0001234	68.43	gold quality
left adrenal gland cortex	UBERON:0035825	68.27	gold quality
body of stomach	UBERON:0001161	68.11	gold quality
ascending aorta	UBERON:0001496	67.79	gold quality
right adrenal gland	UBERON:0001233	67.75	gold quality
omental fat pad	UBERON:0010414	67.23	gold quality
Ammon’s horn	UBERON:0001954	65.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.30

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• demonstrated a novel mechanism of post-transcriptional regulation of ANXA1 expression and identified miR-196a as a marker of esophageal cancer (PMID:18663355)
• The roles of microRNA (miRNA)-196a on adipose tissue-derived mesenchymal stem cells proliferation and osteogenic differentiation. (PMID:19063684)
• Data show that miR-196a exerts a pro-oncogenic influence in colorectal cancer. (PMID:19418581)
• miR-196 directly acts on the 3’-UTR of Bach1 messenger RNA and translationally represses the expression of this protein, and up-regulates HMOX1 (PMID:20127796)
• Data shows the genotype CC of miR-196a (rs11614913) polymorphism is associated with decreased risk of glioma in the Chinese population. (PMID:20229273)
• Strongly reduced expression of the microRNA miR-196a in melanoma cells compared to healthy melanocytes leads to enhanced HOX-B7 mRNA and protein levels, which subsequently raise Ets-1 activity by inducing basic fibroblast growth factor (bFGF). (PMID:20480203)
• Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas. (PMID:20601442)
• Serum miR-196a could be a potential noninvasive marker for pancreatic ductal adenocarcinoma prognosis and selection of laparotomy. (PMID:20614181)
• Loss of miR-196a is associated with melanoma progression. (PMID:21077158)
• Studies indicate that miR-21, miR-196a, and miR-217 are among the diagnostic, predictive, and prognostic microRNA profiling in pancreatic ductal adenocarcinoma. (PMID:22001830)
• Data indicate that miR-15a, miR-16, miR-26ab, miR-196ab and Let-7a as potential HMGA1 and HMGA2-targeting miRNAs. (PMID:22139073)
• Downregulation of miR-196a may be one of the mechanisms by which collagens are highly deposited in keloid tissues. (PMID:22358059)
• data demonstrate that miR-196a exerts an oncogenic role in gastric cancer (PMID:22420029)
• miR-196a induces functional brown adipocytes in white adipose tissue through the suppression of Hoxc8, which functions as a gatekeeper of the inducible brown adipogenesis. (PMID:22545021)
• MiR-196a binding-site single nucleotide polymorphism regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. (PMID:22859270)
• Single nucleotide polymorphisms in pre-miR-196a rs11614913C>T is associated with early-stage non-small-cell lung cancer. (PMID:23470291)
• Low expressions of serum exosomal miR-196A1 is associated with pancreatic cancer. (PMID:24007214)
• regulation of inhibitor of growth 5 (ING5) expression by miR-196a and its impact on apoptosis, invasion, and growth of pancreatic cancer cells (PMID:24048456)
• NTN4 expression was downregulated in cervical cancer tissues compared to normal controls, and in vivo mRNA level of NTN4 inversely correlated with miR-196a expression. (PMID:24120501)
• MIR196A1 polymorphisms are associated with hepatocellular carcinoma. (PMID:24377574)
• We found that the risk for GC was significantly higher for the carriers of miR-149 rs2292832CC (p = 0.009) and miR-196a2 rs11614913CC (p < 0.0001) genotypes, as well as for the carriers of the miR-146a C>G (rs2910164. (PMID:24379078)
• MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibiting IkappaBalpha both in vitro and in vivo. (PMID:24463357)
• Single nucleotide polymorphisms in miR-196a is associated with colorectal cancer susceptibility. (PMID:24568449)
• Data indicate that elevated expression of miR-196a in pancreatic juice samples is predictive of type intraductal papillary mucinous neoplasm of the pancreas (IPMNs). (PMID:24622064)
• Results show that FMRP regulates miR196a-mediated repression of HOXB8 via interaction with the AGO2 MID domain. (PMID:24727796)
• miR-196a was over-expressed in cervical cancer cells, while an absence of HOXC8 expression was observed. (PMID:24817935)
• Genetic polymorphism of miR-196a is associated with breast cancer. (PMID:24922658)
• miR-196 performed it’s their function by inhibiting NME4 expression and further activating p-JNK, suppressing TIMP1, and augmenting MMP1/9. (PMID:25233933)
• miR-196a up-regulation is associated with gastric cancer. (PMID:25374225)
• Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer. (PMID:25485932)
• Study identifies miR-196a as a potential biomarker of prognosis and response of head and neck squamous cell carcinoma (HNSCC) to radio-therapy and suggests that miR-196a and/or its target ANXA1 could represent important therapeutic targets in HNSCC. (PMID:25523631)
• the present study identified circulating miR-196a as a specific and noninvasive candidate biomarker for the diagnosis ofchronic hepatitis C . (PMID:25738504)
• Knock-down of miR-196a expression decreased HNSCC cell migration, invasion and adhesion to fibronectin, but had no effect on proliferation. (PMID:25860510)
• Overexpression of miR-196a promoted proliferation of MG63 and U2OS cells by modulating the PTEN/PI3K/Akt/FOXO1 signaling pathway. (PMID:26045752)
• miR-196a is expressed in small intestinal neuroendocrine tumors and regulates HOXA9, HOXB7, LRP4 and RSPO2 gene expression. (PMID:26052033)
• miR-196a can effect the proliferation, the apoptosis and migration of HepG2 cell lines by gene HOXB8, caspase-3 regulation. (PMID:26054667)
• This meta-analysis showed that rs2910164 and rs2292832 may increase the risk of CRC (hsa-mir-146a rs2910164, hsa-mir-149 rs2292832, hsa-mir-196a2 rs11614913, and hsa-mir-499 rs3746444). rs11614913 and rs3746444 polymorphism may reduce the risk of CRC. (PMID:26078942)
• miR-196a may play an important role in the progression of ovarian carcinoma, and could be used as an independent prognostic biomarker for patients with ovarian carcinoma. (PMID:26097603)
• Combination of high-miR-196a and low-miR-367 expression may be a novel biomarker in identifying a poor prognosis group of high-grade glioma. (PMID:26261539)
• High miRNA-196a expression in pancreatic neuroendocrine tumors was associated with stage, mitotic count, and decreased survival. (PMID:26683934)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
rattus_norvegicus	Mir196c	ENSRNOG00000035510

Paralogs (2): MIR196A2 (ENSG00000207924), MIR196B (ENSG00000283745)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.